Aktienanalyse zu Achieve Life Sciences, Inc. (ACHV)ACHVAchieve Life Sciences, Inc.

Achieve Life Sciences, Inc. is a late-stage specialty pharmaceutical company. The Company focuses on addressing the global smoking health and nicotine dependence epidemic through the development and commercialization of cytisinicline. It has completed two Phase III studies with cytisinicline for smoking cessation and one Phase II study with cytisinicline in vaping cessation. Cytisinicline is a naturally occurring, plant-based alkaloid. Cytisinicline is structurally similar to nicotine and has a dual-acting mechanism of action, being both a receptor agonist and antagonist. Cytisinicline is an investigational product candidate being developed for the treatment of nicotine dependence and has not been approved by the Food and Drug Administration for any indication in the United States. Cytisinicline acts as a partial agonist/antagonist, binding to alpha-4 beta-2 nicotinic receptors in the brain and is thought to have two potential consequences in treating nicotine dependence. It operates in the Healthcare sector (IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES industry).

Achieve Life Sciences Inc (ACHV) is a good buy right now due to its current price of $7.41, which is significantly below the analyst consensus target price of $14.11, indicating a potential upside of 89.7%. Additionally, the stock has shown a year-to-date change of +49.09% and a one-year change of +139.03%, reflecting strong momentum. The main risk to consider is the negative earnings per share (EPS) of -0.80 reported for Q2 2026, indicating ongoing losses, but the company's promising drug pipeline could offset this risk in the long term.

1 analysts cover ACHV: 1 rate it Buy, 0 Hold and 0 Sell. The average price target is 15.50.